6-ethoxy-pyridine-2-carboxylic acid methyl ester | 55980-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-ethoxy-pyridine-2-carboxylic acid methyl ester
• 英文别名: Methyl 6-ethoxypicolinate；methyl 6-ethoxypyridine-2-carboxylate
• CAS: 55980-65-9
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: OZZDMTGIQASJLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• TRIAZOLE AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170044131A1

  公开（公告）日：2017-02-16

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用可接受的盐，任何上述的立体异构体，或其混合物均为APJ受体激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构：其中变量的定义在此处提供。
• METHODS OF TREATING HEART FAILURE
  申请人：AMGEN INC.

  公开号：US20170281625A1

  公开（公告）日：2017-10-05

  Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

  治疗心力衰竭的方法包括向患有心力衰竭的受试者投予一种有效量的三唑化合物，该化合物是APJ受体的激动剂，或其药学上可接受的盐，或两者的混合物。本文提供了特别适用于此类方法的化合物。
• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
  申请人：Annapurna Bio, Inc.

  公开号：US20220125787A1

  公开（公告）日：2022-04-28

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.
• US9573936B2
  申请人：——

  公开号：US9573936B2

  公开（公告）日：2017-02-21
• US9656997B2
  申请人：——

  公开号：US9656997B2

  公开（公告）日：2017-05-23